Progress of concurrent chemoradiotherapy in esophageal cancer
10.3760/cma.j.cn115355-20190920-00425
- VernacularTitle:同步放化疗在食管癌中的研究进展
- Author:
Yunxiao WANG
1
;
Zhongchao HUO
;
Xiu JIN
;
Xuetao HAN
;
Yun DONG
Author Information
1. 河北工程大学临床医学院，河北 邯郸 056000
- From:
Cancer Research and Clinic
2020;32(6):436-441
- CountryChina
- Language:Chinese
-
Abstract:
Esophageal cancer is the most common malignant tumors in the digestive system. The treatments include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy. In order to prolong the survival time and reduce the recurrence rate, most of the patients with locally advanced esophageal cancer were treated with combined radiotherapy and chemotherapy. There are many ways of concurrent chemoradiotherapy, together with the application of molecular targeting and immune drugs in esophageal cancer, there are different modes of combined therapy, which are of great significance to improve clinical efficacy and treatment compliance. This article reviews the progress of concurrent chemoradiotherapy for esophageal cancer in recent years.
